Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial.

Thiele, Holger; Desch, Steffen; Piek, Jan J; Stepinska, Janina; Oldroyd, Keith; Serpytis, Pranas; Montalescot, Gilles; Noc, Marko; Huber, Kurt; Fuernau, Georg; de Waha, Suzanne; Meyer-Saraei, Roza; Schneider, Steffen; Windecker, Stephan; Savonitto, Stefano; Briggs, Andrew; Torremante, Patrizia; Vrints, Christiaan; Schuler, Gerhard; Ceglarek, Uta; ... (2016). Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 172, pp. 160-169. Elsevier 10.1016/j.ahj.2015.11.006

[img] Text
1-s2.0-S0002870315006638-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (937kB) | Request a copy

BACKGROUND In acute myocardial infarction complicated by cardiogenic shock (CS), up to 80% of patients present with multivessel coronary artery disease. Currently, the best revascularization strategy is unknown. Therefore, a prospective randomized adequately powered clinical trial is warranted. STUDY DESIGN The CULPRIT-SHOCK study is a 706-patient controlled, international, multicenter, randomized, open-label trial. It is designed to compare culprit lesion only percutaneous coronary intervention (PCI) with possible staged non-culprit lesion revascularization versus immediate multivessel PCI in patients with CS complicating acute myocardial infarction. Patients will be randomized in a 1:1 fashion to one of the two treatment arms. The primary efficacy endpoint of CULPRIT-SHOCK is 30-day mortality and severe renal failure requiring renal replacement therapy. Secondary outcome measures such as hemodynamic, laboratory, and clinical parameters will serve as surrogate endpoints for prognosis. Furthermore, an intermediate- and long-term follow-up at 6 and 12 months will be performed. Safety endpoints include the assessment of bleeding and stroke. CONCLUSIONS The CULPRIT-SHOCK trial will address the question of optimal revascularization strategy in patients with multivessel disease and acute myocardial infarction complicated by CS.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0002-8703

Publisher:

Elsevier

Language:

English

Submitter:

Judith Liniger

Date Deposited:

29 Dec 2016 08:01

Last Modified:

29 Dec 2016 08:01

Publisher DOI:

10.1016/j.ahj.2015.11.006

PubMed ID:

26856228

BORIS DOI:

10.7892/boris.90381

URI:

https://boris.unibe.ch/id/eprint/90381

Actions (login required)

Edit item Edit item
Provide Feedback